(Q35744425)

10 August 2017

1 reference

title

Pharmacokinetic enhancement of protease inhibitor therapy (English)

1 reference

10 August 2017

1 reference

Jennifer R King

1

1 reference

10 August 2017

Heather Wynn

series ordinal

2

1 reference

10 August 2017

Richard Brundage

series ordinal

3

1 reference

10 August 2017

Edward P Acosta

series ordinal

4

1 reference

10 August 2017

publication date

1 January 2004

1 reference

Clinical Pharmacokinetics

10 August 2017

published in

1 reference

10 August 2017

volume

43

1 reference

10 August 2017

issue

5

1 reference

10 August 2017

page(s)

291-310

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200443050-00003

10 August 2017

exact match

0 references

cites work

Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir

1 reference

12 December 2020

Structure and function of P-glycoprotein in normal liver and small intestine

1 reference

12 December 2020

Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir

1 reference

12 December 2020

Pharmacokinetic interaction between lopinavir/r and amprenavir in salvage therapy

1 reference

12 December 2020

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

12 December 2020

Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy

1 reference

12 December 2020

Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients

1 reference

12 December 2020

Unfavourable interaction of amprenavir and lopinavir in combination with ritonavir?

1 reference

12 December 2020

Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens

1 reference

12 December 2020

Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults

1 reference

12 December 2020

Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure

1 reference

12 December 2020

Ritonavir and saquinavir combination therapy for the treatment of HIV infection

1 reference

12 December 2020

Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals

1 reference

12 December 2020

Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection

1 reference

12 December 2020

Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients

1 reference

12 December 2020

Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate

1 reference

12 December 2020

Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration

1 reference

12 December 2020

The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals

1 reference

12 December 2020

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients

1 reference

12 December 2020

In vitro antiviral interaction of lopinavir with other protease inhibitors

1 reference

12 December 2020

Recent developments in HIV protease inhibitor therapy

1 reference

12 December 2020

Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers

1 reference

12 December 2020

Dose-finding study of a once-daily indinavir/ritonavir regimen

1 reference

12 December 2020

Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir

1 reference

12 December 2020

pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs

1 reference

12 December 2020

Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir

1 reference

12 December 2020

Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients

1 reference

12 December 2020

Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir

1 reference

12 December 2020

Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir

1 reference

12 December 2020

Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors

1 reference

12 December 2020

Single-dose pharmacokinetics of indinavir and the effect of food.

1 reference

12 December 2020

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

1 reference

12 December 2020

ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease

1 reference

12 December 2020

Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors

1 reference

12 December 2020

Resistance to human immunodeficiency virus type 1 protease inhibitors.

1 reference

12 December 2020

Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations

1 reference

12 December 2020

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.

1 reference

12 December 2020

Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir

1 reference

12 December 2020

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

1 reference

12 December 2020

Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy

1 reference

12 December 2020

A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy

1 reference

12 December 2020

Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy.

1 reference

12 December 2020

Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir.

1 reference

12 December 2020

Low-dose ritonavir moderately enhances nelfinavir exposure

1 reference

12 December 2020

Effect of reduced-dose amprenavir in combination with lopinavir on plasma levels of amprenavir in patients infected with HIV.

1 reference

12 December 2020

The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study

1 reference

12 December 2020

10.2165/00003088-200443050-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

10 August 2017

1018837390

0 references

1 reference